The drugmaker said the dosing cups for the lot of Robitusson are missing the 5 mL and 10 mL markings, and the dosing cups for the Dimetapp cough syrup are missing the 10 mL markings.
There’s a potential risk of accidental overdose if consumers don’t notice the discrepancies between the cups’ markings and the recommended dosages on the medication’s instructions, GlaxoSmithKline said.
Symptoms of overdose of both medicines include impaired coordination, elevation in blood pressure or heart rate, lack of energy and severe dizziness or drowsiness.
GlaxoSmithKline said it hasn’t received any adverse event reports related to the recall.
The recalled lots were distributed nationwide between February and June. Wholesalers, distributors and retailers should stop distributing the recalled lots and quarantine them.
Read the FDA’s full news release here.
More articles on pharmacy:
Kaiser Permanente joins Civica Rx to supply generic drugs
Nearly 90% of Americans worried about drug price hikes
FTC didn’t follow its own rules in OK of Allergan takeover, California says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
